Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

A triad of NRP2, DLX and p53 proteins in lung cancer metastasis.

Drabkin HA, Starkova J, Gemmill RM.

Oncotarget. 2017 Oct 26;8(57):96464-96465. doi: 10.18632/oncotarget.22097. eCollection 2017 Nov 14. No abstract available.

2.

Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.

Roche J, Gemmill RM, Drabkin HA.

Cancers (Basel). 2017 Jun 24;9(7). pii: E72. doi: 10.3390/cancers9070072. Review.

3.

The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.

Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA.

Sci Signal. 2017 Jan 17;10(462). pii: eaag0528. doi: 10.1126/scisignal.aag0528.

4.

Urothelial carcinoma of donor origin in a kidney transplant patient.

Michel Ortega RM, Wolff DJ, Schandl CA, Drabkin HA.

J Immunother Cancer. 2016 Oct 18;4:63. eCollection 2016.

5.

A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.

Pal SK, Drabkin HA, Reeves JA, Hainsworth JD, Hazel SE, Paggiarino DA, Wojciak J, Woodnutt G, Bhatt RS.

Cancer. 2017 Feb 15;123(4):576-582. doi: 10.1002/cncr.30393. Epub 2016 Oct 11.

6.

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.

PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016.

7.

Nivolumab in renal cell carcinoma.

Michel Ortega RM, Drabkin HA.

Expert Opin Biol Ther. 2015 Jul;15(7):1049-60. doi: 10.1517/14712598.2015.1049596. Epub 2015 Jun 3. Review.

PMID:
26038957
8.

Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations.

Skvarova Kramarzova K, Fiser K, Mejstrikova E, Rejlova K, Zaliova M, Fornerod M, Drabkin HA, van den Heuvel-Eibrink MM, Stary J, Trka J, Starkova J.

J Hematol Oncol. 2014 Dec 24;7:94. doi: 10.1186/s13045-014-0094-0.

9.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ.

J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.

10.

The emerging role of class-3 semaphorins and their neuropilin receptors in oncology.

Nasarre P, Gemmill RM, Drabkin HA.

Onco Targets Ther. 2014 Sep 24;7:1663-87. doi: 10.2147/OTT.S37744. eCollection 2014. Review.

11.

Analysis of the t(3;8) of hereditary renal cell carcinoma: a palindrome-mediated translocation.

Kato T, Franconi CP, Sheridan MB, Hacker AM, Inagakai H, Glover TW, Arlt MF, Drabkin HA, Gemmill RM, Kurahashi H, Emanuel BS.

Cancer Genet. 2014 Apr;207(4):133-40. doi: 10.1016/j.cancergen.2014.03.004. Epub 2014 Mar 18.

12.

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA.

Invest New Drugs. 2014 Feb;32(1):178-87. doi: 10.1007/s10637-013-0045-6. Epub 2013 Nov 16.

13.

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA.

Cancer Res. 2013 Dec 1;73(23):7111-21. doi: 10.1158/0008-5472.CAN-13-1755. Epub 2013 Oct 11. Erratum in: Cancer Res. 2014 Jan 15;74(2):637.

14.

Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors.

Chakravarty S, Lai WC, Zou Y, Drabkin HA, Gemmill RM, Simon GR, Chin SH, Chen RT.

Biosens Bioelectron. 2013 May 15;43:50-5. doi: 10.1016/j.bios.2012.11.012. Epub 2012 Nov 27.

15.

Cholesterol and the development of clear-cell renal carcinoma.

Drabkin HA, Gemmill RM.

Curr Opin Pharmacol. 2012 Dec;12(6):742-50. doi: 10.1016/j.coph.2012.08.002. Epub 2012 Aug 30. Review.

PMID:
22939900
16.

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR.

Invest New Drugs. 2013 Feb;31(1):115-25. doi: 10.1007/s10637-012-9812-z. Epub 2012 Mar 14.

PMID:
22415798
17.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA.

Invest New Drugs. 2012 Dec;30(6):2303-17. doi: 10.1007/s10637-011-9766-6. Epub 2011 Nov 12.

PMID:
22080430
18.

Functional analysis of the NUP98-CCDC28A fusion protein.

Petit A, Ragu C, Soler G, Ottolenghi C, Schluth C, Radford-Weiss I, Schneider-Maunoury S, Callebaut I, Dastugue N, Drabkin HA, Bernard OA, Romana S, Penard-Lacronique V.

Haematologica. 2012 Mar;97(3):379-87. doi: 10.3324/haematol.2011.047969. Epub 2011 Nov 4.

19.

Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling.

Starkova J, Gadgil S, Qiu YH, Zhang N, Hermanova I, Kornblau SM, Drabkin HA.

Haematologica. 2011 Jun;96(6):820-8. doi: 10.3324/haematol.2010.031179. Epub 2011 Feb 28.

20.

ZEB1-responsive genes in non-small cell lung cancer.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA.

Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.

21.

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.

Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.

Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20.

PMID:
20733337
22.

A palindrome-mediated recurrent translocation with 3:1 meiotic nondisjunction: the t(8;22)(q24.13;q11.21).

Sheridan MB, Kato T, Haldeman-Englert C, Jalali GR, Milunsky JM, Zou Y, Klaes R, Gimelli G, Gimelli S, Gemmill RM, Drabkin HA, Hacker AM, Brown J, Tomkins D, Shaikh TH, Kurahashi H, Zackai EH, Emanuel BS.

Am J Hum Genet. 2010 Aug 13;87(2):209-18. doi: 10.1016/j.ajhg.2010.07.002. Epub 2010 Jul 30.

23.

HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL.

Starkova J, Zamostna B, Mejstrikova E, Krejci R, Drabkin HA, Trka J.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1072-82. doi: 10.1002/pbc.22749.

PMID:
20672366
24.

Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC).

Drabkin HA, Gemmill RM.

Adv Cancer Res. 2010;107:39-56. doi: 10.1016/S0065-230X(10)07002-8. Review.

PMID:
20399960
25.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

26.

The TRC8 ubiquitin ligase is sterol regulated and interacts with lipid and protein biosynthetic pathways.

Lee JP, Brauweiler A, Rudolph M, Hooper JE, Drabkin HA, Gemmill RM.

Mol Cancer Res. 2010 Jan;8(1):93-106. doi: 10.1158/1541-7786.MCR-08-0491. Epub 2010 Jan 12.

27.

Pazopanib and anti-VEGF therapy.

Drabkin HA.

Open Access J Urol. 2010 Mar 12;2:35-40. Review.

28.

Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.

Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, Gemmill RM.

J Thorac Oncol. 2009 Dec;4(12):1455-65. doi: 10.1097/JTO.0b013e3181bc9419.

29.

The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER.

Stagg HR, Thomas M, van den Boomen D, Wiertz EJ, Drabkin HA, Gemmill RM, Lehner PJ.

J Cell Biol. 2009 Sep 7;186(5):685-92. doi: 10.1083/jcb.200906110. Epub 2009 Aug 31.

30.

The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma.

Gimelli S, Beri S, Drabkin HA, Gambini C, Gregorio A, Fiorio P, Zuffardi O, Gemmill RM, Giorda R, Gimelli G.

Mol Cancer. 2009 Jul 30;8:52. doi: 10.1186/1476-4598-8-52.

31.

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.

Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE.

Cancer. 2009 Oct 15;115(20):4737-44. doi: 10.1002/cncr.24543.

32.

ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J.

Neoplasia. 2009 Feb;11(2):157-66.

33.

HOX expression patterns identify a common signature for favorable AML.

Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA.

Leukemia. 2008 Nov;22(11):2041-7. doi: 10.1038/leu.2008.198. Epub 2008 Jul 31.

34.

Semaphorins and their receptors in lung cancer.

Potiron VA, Roche J, Drabkin HA.

Cancer Lett. 2009 Jan 8;273(1):1-14. doi: 10.1016/j.canlet.2008.05.032. Epub 2008 Jul 14. Review.

35.

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

Costa LJ, Drabkin HA.

Oncologist. 2007 Dec;12(12):1404-15. doi: 10.1634/theoncologist.12-12-1404. Review.

36.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D.

J Clin Oncol. 2007 Oct 10;25(29):4536-41. Epub 2007 Sep 17.

PMID:
17876014
37.

Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.

Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA.

Cancer Res. 2007 Sep 15;67(18):8708-15.

38.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED; Southwest Oncology Group.

J Clin Oncol. 2007 Aug 1;25(22):3296-301.

PMID:
17664477
39.

A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma.

Poland KS, Azim M, Folsom M, Goldfarb R, Naeem R, Korch C, Drabkin HA, Gemmill RM, Plon SE.

Genes Chromosomes Cancer. 2007 Sep;46(9):805-12.

PMID:
17539022
40.

Semaphorins in lung cancer.

Clarhaut J, Roche J, Drabkin HA.

J Thorac Oncol. 2006 Mar;1(3):203-4. Review. No abstract available.

41.

Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.

Costa LJ, Gemmill RM, Drabkin HA.

Urology. 2007 Mar;69(3):596-602.

PMID:
17382186
42.

RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene.

Brauweiler A, Lorick KL, Lee JP, Tsai YC, Chan D, Weissman AM, Drabkin HA, Gemmill RM.

Oncogene. 2007 Apr 5;26(16):2263-71. Epub 2006 Oct 2.

PMID:
17016439
43.

Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM.

Cancer Res. 2006 May 15;66(10):5338-45.

44.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr.

Cancer Res. 2006 Jan 15;66(2):944-50.

45.

Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene.

Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J.

Biochim Biophys Acta. 2005 Jul 25;1730(1):66-76.

PMID:
16005989
46.

[Semaphorins and cancers : an up 'dating'].

Nasarre P, Constantin B, Drabkin HA, Roche J.

Med Sci (Paris). 2005 Jun-Jul;21(6-7):641-7. Review. French.

47.

Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J.

Neoplasia. 2005 May;7(5):457-65.

48.

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.

Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA.

Br J Cancer. 2005 Jun 20;92(12):2266-77.

49.

Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.

Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J.

Neoplasia. 2005 Feb;7(2):180-9.

50.

Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5.

Gemmill RM, Lee JP, Chamovitz DA, Segal D, Hooper JE, Drabkin HA.

Oncogene. 2005 May 12;24(21):3503-11.

PMID:
15735686

Supplemental Content

Loading ...
Support Center